Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Orforglipron

IBI3042 Study in Healthy Participants and Overweight or Obese Participants

Eli Lilly · Phase 1 · Recruiting · Enrollment 104

NCT07793019

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Investigational Drug: IBI3042 (Part A)n/rn/rn/rn/r
Investigational Drug: IBI3042 (Part B)n/rn/rn/rn/r
Matching Placebo (Part B)n/rn/rn/rn/r
Orforglipron (Part B)n/rn/rn/rn/r
Matching Placebo (Part A)n/rn/rn/rn/r

Not shown

  • Investigational Drug: IBI3042 (Part A): endpoint not reported
  • Investigational Drug: IBI3042 (Part B): endpoint not reported
  • Matching Placebo (Part B): endpoint not reported
  • Orforglipron (Part B): endpoint not reported
  • Matching Placebo (Part A): endpoint not reported